KORU Medical Systems, Inc. ( KRMD ) NASDAQ Capital Market

Cena: 4.39 ( 6.81% )

Aktualizacja 08-22 21:58
NASDAQ Capital Market
Branża: Medical - Instruments & Supplies
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Koru Medical Systems, Inc. Projektuje, producenci i rynkowe przenośne urządzenia medyczne przede wszystkim na rynku infuzji ambulatoryjnej w Stanach Zjednoczonych i na arenie międzynarodowej. Oferuje mechaniczny produkt infuzyjny obejmujący systemy infuzyjne Freedom, które obejmują sterownik strzykawki Freedom60, sterownik strzykawki FreedomEdge, podskórne zestawy igły podskórnej i precyzyjne rurki przepływowe. Firma zapewnia również materiały edukacyjne i szkolenia dla klinicystów, pacjentów i zwolenników pacjentów. Sprzedaje swoje produkty za pośrednictwem dystrybutorów sprzedaży bezpośredniej i urządzeń medycznych, a także online. Koru Medical Systems, Inc. został zarejestrowany w 1980 roku i ma siedzibę w Chester w Nowym Jorku.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Instruments & Supplies
Zatrudnienie: 82
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 95.9511
Ilość akcji: Brak danych
Debiut giełdowy: 1994-04-05
WWW: https://www.korumedical.com
CEO: Ms. Linda M. Tharby
Adres: 24 Carpenter Road
Siedziba: 10918 Chester
ISIN: US7599101026
Wskaźniki finansowe
Kapitalizacja (USD) 202 971 650
Aktywa: 27 390 032
Cena: 4.39
Wskaźnik Altman Z-Score: 10.3
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -43.9
Ilość akcji w obrocie: 96%
Średni wolumen: 239 333
Ilość akcji 46 235 000
Wskaźniki finansowe
Przychody TTM 31 993 796
Zobowiązania: 9 656 552
Przedział 52 tyg.: 1.86 - 5.05
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -0.1
P/E branży: 29.7
Beta: 0.41
Raport okresowy: 2025-11-05
WWW: https://www.korumedical.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Linda M. Tharby President, Chief Executive Officer & Director 713 369 1968
Mr. Thomas Adams Chief Financial Officer, Secretary & Treasurer 380 467 1973
Mr. Brian Case Chief Technology Officer 371 157 1973
Mr. Kenneth Miller Chief Commercial Officer 126 537 1969
Mr. Christopher Pazdan Chief Operating Officer 0 0
Mr. Rob Cannon Vice President of Sales 0 0
Lista ETF z ekspozycją na akcje KORU Medical Systems, Inc.
Symbol ETF Ilość akcji Wartość
IWM 683 886 2 366 244
IWO 378 591 1 309 926
VTWO 216 235 774 121
IWC 95 910 331 850
GSSC 48 305 181 143
VTWG 37 794 135 302
RSSL 21 458 74 244
XSU.TO 4 870 23 474
UWM 4 298 14 871
URTY 3 558 12 310
DFAC 3 122 10 802
HDG 51 176
SC0K.DE 0 12 158
RTYS.L 0 13 876
Wiadomości dla KORU Medical Systems, Inc.
Tytuł Treść Źródło Aktualizacja Link
KORU Medical Systems, Inc. (KRMD) Q1 2025 Earnings Call Transcript KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Louisa Smith - Investor Relations Linda Tharby - Chief Executive Officer and President Tom Adams - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Chase Knickerbocker - Craig-Hallum Jason Bednar - Piper Sandler Anderson Schock - B. Riley Securities Operator Greetings, and welcome to KORU Medical Systems First Quarter 2025 Earnings Conference Call. seekingalpha.com 2025-05-11 12:12:30 Czytaj oryginał (ang.)
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.02 per share a year ago. zacks.com 2025-05-07 22:50:39 Czytaj oryginał (ang.)
KORU Medical Systems, Inc. (KRMD) Q4 2024 Earnings Call Transcript KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q4 2024 Earnings Conference Call March 12, 2025 4:30 PM ET Company Participants Louisa Smith - Investor Relations Linda Tharby - Chief Executive Officer and President Tom Adams - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Capital Group Frank Takkinen - Lake Street Capital Markets Jason Bednar - Piper Sandler Anderson Shack - B. Riley Securities Michaela Smith - Canaccord Operator Greetings. seekingalpha.com 2025-03-13 00:34:53 Czytaj oryginał (ang.)
KORU Medical Systems to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that. businesswire.com 2025-02-19 18:05:00 Czytaj oryginał (ang.)
KORU Medical Systems Has A Long Runway KORU Medical Systems' stock has surged 60% since November, driven by the success of its FREEDOM System for subcutaneous immunoglobulin delivery. The SCIg market is growing rapidly, with KORU outperforming competitors by capturing market share and benefiting from trends like prefilled syringes. Strong international growth, new therapies, and product innovations are key drivers, with significant revenue from recurring patients and promising future launches. seekingalpha.com 2025-02-10 02:11:27 Czytaj oryginał (ang.)
KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunogl. businesswire.com 2025-02-06 18:05:00 Czytaj oryginał (ang.)
KORU Medical Systems Inc. (KRMD) is a Great Momentum Stock: Should You Buy? Does KORU Medical Systems Inc. (KRMD) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com 2025-01-24 15:01:26 Czytaj oryginał (ang.)
KORU Medical Systems to Participate in Piper Sandler's 36th Annual Healthcare Conference MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in Piper Sandler's 36th Annual Healthcare Conference on December 5, 2024. KORU Medical's management is scheduled to present at Piper Sandler's 36th Annual Healthcare. businesswire.com 2024-11-25 18:05:00 Czytaj oryginał (ang.)
KORU Medical Systems, Inc. (KRMD) Q3 2024 Earnings Call Transcript KORU Medical Systems, Inc. (KRMD) Q3 2024 Earnings Call Transcript seekingalpha.com 2024-11-13 20:57:32 Czytaj oryginał (ang.)
KORU Medical Systems Inc. (KRMD) Reports Q3 Loss, Tops Revenue Estimates KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago. zacks.com 2024-11-13 20:16:10 Czytaj oryginał (ang.)
KORU Medical Systems, Inc. Announces 2024 Q3 Financial Results, Third Consecutive Quarter of Double-Digit Growth; Raises Full Year 2024 Guidance MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2024, and raised full year 2024 revenue, gross margin, and year-end cash guidance. Recent Highlights Third quarter 2024 net revenues of $8. businesswire.com 2024-11-13 18:05:00 Czytaj oryginał (ang.)
KORU Medical Systems to Participate in Upcoming Investor Conferences MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in two upcoming Investor Conferences. KORU Medical's management team is participating at the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, Novemb. businesswire.com 2024-11-06 18:05:00 Czytaj oryginał (ang.)
Impressive Turnaround At KORU Medical KORU Medical Systems is poised for growth with solid revenue increases, multiple growth drivers, and a chance to reach cash flow breakeven in Q4. The FREEDOM system, designed for at-home drug delivery, offers recurring revenue from consumables and is gaining market share in the SCIg market. International expansion and novel therapies present significant growth opportunities, with international revenue growing 46% and novel therapies progressing to Phase 3 trials. seekingalpha.com 2024-11-06 10:34:27 Czytaj oryginał (ang.)
KORU Medical Systems, Inc (KRMD) Q2 2024 Earnings Call Transcript KORU Medical Systems, Inc (KRMD) Q2 2024 Earnings Call Transcript seekingalpha.com 2024-08-08 00:52:19 Czytaj oryginał (ang.)
KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago. zacks.com 2024-08-07 22:41:08 Czytaj oryginał (ang.)
Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know KORU Medical Systems Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-07-31 15:06:09 Czytaj oryginał (ang.)
KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan KORU Medical (KRMD) announces the receipt of regulatory clearance for its FreedomEdge System in Japan. zacks.com 2024-07-03 17:30:19 Czytaj oryginał (ang.)
Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, are joining forces to offer a high-volume subcutaneous drug infusion solution. “We want to ensure that medications are safe and easy to use for. businesswire.com 2024-06-05 13:00:00 Czytaj oryginał (ang.)
KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical company to initiate a feasibility study with KORU Medical's Freedom Infusion System (the “Freedom System”) for an FDA and EMA approved subcutaneous onco. businesswire.com 2024-06-04 20:03:00 Czytaj oryginał (ang.)
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce the signing of a Phase III clinical supply agreement for a novel enzyme replacement therapy to treat a rare endocrinological disease. This significant milestone marks the progression of this. businesswire.com 2024-05-14 20:05:00 Czytaj oryginał (ang.)
KORU Medical Systems, Inc. (KRMD) Q1 2024 Earnings Call Transcript KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Louisa Smith - The Gilmartin Group Linda Tharby - President & Chief Executive Officer Tom Adams - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum William Wood - B. Riley Securities Caitlin Cronin - Canaccord Genuity Joseph Downing - Piper Sandler Operator Greetings and welcome to the KORU Medical Systems' First Quarter 2024 Financial Results Conference Call and Webcast. seekingalpha.com 2024-05-02 02:11:08 Czytaj oryginał (ang.)
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago. zacks.com 2024-05-01 23:21:11 Czytaj oryginał (ang.)
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights First quarter 2024 net revenues of $8.2 million, an 11% increase over the prior year and record high quarterly revenue. businesswire.com 2024-05-01 20:05:00 Czytaj oryginał (ang.)
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024 MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 1, 2024. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the fina. businesswire.com 2024-04-17 11:00:00 Czytaj oryginał (ang.)
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a successful appeal related to an ongoing audit by its notified body in the EU, The British Standards Institute (BSI). The Company's appeal of an assessment report from BSI regarding a recommendati. businesswire.com 2024-04-11 20:05:00 Czytaj oryginał (ang.)
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return. investorplace.com 2024-03-28 16:28:50 Czytaj oryginał (ang.)
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce data on the impact of the Freedom Infusion System on subcutaneous immunoglobulin (SCIg) therapy for primary immunodeficiency diseases (PIDD) to be presented at the National Home Infusion Ass. businesswire.com 2024-03-18 19:24:00 Czytaj oryginał (ang.)